Showing 1651-1660 of 18593 results for "".
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
https://reachmd.com/programs/project-oncology/one-year-or-two-dante-trial-explores-immunotherapy-duration-in-metastatic-melanoma/33002/The DANTE phase III trial investigated if stopping anti–PD-1 therapy at one year yields comparable outcomes to longer treatment in metastatic melanoma. Read more about the findings and their potential clinical implications.Personalizing Prostate Cancer Surveillance: Insights from Canary PASS
https://reachmd.com/programs/frontlines-prostate-cancer/personalizing-prostate-cancer-surveillance-insights-from-canary-pass/32224/For patients with early-stage prostate cancer, routine clinical variables like Gleason scores or PSAs have their limits. The Canary Prostate Active Surveillance Study (Canary PASS) is reshaping our management approach through improved risk stratification. Dr. Lisa Newcomb joins us to explain the finMasterclasses in Dermatology: The Importance of Interdisciplinary Teaching
https://practicaldermatology.com/conferences/masterclasses-in-dermatology-2025/masterclasses-in-dermatology-the-importance-of-interdisciplinary-teaching/33021/Masterclasses in Dermatology 2025 course directors Alice Gottlieb, MD, a dermatologist and rheumatologist at Mount Sinai, and Joseph Merola, MD, MMSc, chair and professor of dermatology at UT Southwestern Medical Center in Dallas, talk about the value of interdisciplinary education and collaborationPromising Results for Investigational Antisense Oligonucleotide Treatment for Dravet Syndrome
https://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/promising-results-for-investigational-antisense-oligonucleotide-treatment-for-dravet-syndrome-1/35435/Joseph Sullivan, MD, Professor, UCSF School of Medicine, San Francisco, CA, describes encouraging results from the SWALLOWTAIL and LONGWING studies of an investigational treatment for individuals with Dravet syndrome, including outcomes related to seizure frequency, cognition, and behavior.Extraintestinal Manifestations of IBD: Evaluation and Management Strategies
https://reachmd.com/programs/gi-insights/extraintestinal-manifestations-of-ibd-evaluation-and-management-strategies/27077/Hear how to properly evaluate and manage patients with extraintestinal manifestations of inflammatory bowel disease.A Quick Guide: Principles of Trauma-Informed Care
https://reachmd.com/programs/clinicians-roundtable/tbd/15698/How can clinicians improve trauma patient care in the ED? Read more.Illinois House Bill Protects Physician Mental Health
https://reachmd.com/programs/clinicians-roundtable/illinois-house-bill-protects-physician-mental-health/15465/Illinois recently passed a bill aimed at protecting physicians’ mental health. Here’s what you need to know.Gravity & the Gut: Exploring a Key Hypothesis for IBS
https://reachmd.com/programs/gi-insights/gravity-the-gut-exploring-a-key-hypothesis-for-ibs/14613/Find out more about a possible cause of IBS, and how it might impact treatment.Insights from Obesity Canada: A Deep Dive into Guideline Updates
https://reachmd.com/programs/diabetes-discourse/insights-from-obesity-canada-a-deep-dive-into-guideline-updates/14614/Get the latest pharmacotherapy updates from Obesity Canada and find out how these updated recommendations may impact clinical practice.Exploring Therapeutic Drug Monitoring in IBD
https://reachmd.com/programs/gi-insights/exploring-therapeutic-drug-monitoring-in-ibd/13463/What do we need to know about therapeutic drug monitoring for patients with irritable bowel disease?